PI3K-delta Inhibitor TGR-1202

Known as: TGR-1202 
An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with… (More)

Topic mentions per year

Topic mentions per year

2015-2017
012320152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Umbralisib (TGR-1202) is a novel next-generation inhibitor of phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3K… (More)
Is this relevant?
2017
2017
Phosphoinositide 3-kinase (PI3K) and the proteasome pathway are both involved in activating the mechanistic target of rapamycin… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
Review
2017
Review
2017
INTRODUCTION Over the last few years, several new synthetic drugs, particularly Bruton's tyrosine kinase (BTK… (More)
Is this relevant?
Review
2017
Review
2017
Efficacy, safety and mechanisms of action of novel agents in marginal zone lymphoma patients, both with a nodal and extranodal… (More)
  • table 1
  • table 2
Is this relevant?
2016
2016
Despite a variety of novel therapeutic options in Hodgkin lymphoma (HL), treatment of primary refractory and earlyrelapsed… (More)
  • figure 1
  • figure 2
Is this relevant?
Review
2016
Review
2016
Constitutive or mutational activation of the phosphatidylinositol 3 kinase, or PI3K, has been implicated in many cancers… (More)
Is this relevant?
2015
2015
n ew s 7069, http://meetinglibrary.asco.org/ content/152042–156). This drug lacks the liver and gastrointestinal side effects… (More)
Is this relevant?